ClinicalTrials.gg
Not yet recruitingNCT06974682Updated Aug 27, 2025

Effect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest

An observational study in Cardiac Arrest (CA), sponsored by Capital Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Capital Medical University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.

Planned enrollment
24th of 28
35 · median 300
Started
2025
with 5 others
Observational
28 of 37
13 open now
Primary completion
2027-06
later than 11 of 21 live
Registered
33rd of 37
by date
Lead sponsor
4 of 37
Capital Medical University

Among the 37 studies in Heart Arrest with a site in China, this one is the 24th largest by planned enrollment of the 28 observational ones that give a count, is one of 6 that started in 2025, is one of 28 observational ones, reaches primary completion later than 11 of the 21 other live ones, and was the 33rd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Arrest with a site in China, or all of them as a file.
02

Study summary

Based on the self-control design, this study explored the dynamic regulation of target temperature management therapy (TTM) on intestinal flora structure and metabolites of patients after cardiopulmonary resuscitation (CPR). This study is a single-center prospective observational study. Patients with spontaneous circulation recovery (ROSC) after CPR and TTM were included before and after self-hypothermia treatment, and the time series changes of intestinal flora and metabolites at some representative time points before and after treatment were compared. Thirty-five adult patients (age ≥18 years) who met the admission criteria were included. Before TTM treatment (0h after ROSC, baseline), 48 h after TTM warming (T1) and 48 h after rewarming (T2), fecal samples (macro-gene sequencing) and blood samples (metabonomics) were collected to analyze the changes of intestinal flora and metabolites in patients with cardiac arrest, and to screen the differential flora and metabolites regulated by TTM and their dynamic correlation.

03

Conditions studied

  • Cardiac Arrest (CA)

Browse trials for

Keywords

  • Cardiac Arrest
  • intestinal flora
  • Intestinal metabolites
  • Macrogenome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients after successful cardiopulmonary resuscitation (CPR) were transferred to the emergency intensive care unit for further standardized management.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1).18 years old and above; (2) Successful resuscitation after cardiopulmonary resuscitation (including chest compressions, electric shock defibrillation, etc.) and target temperature management;

Exclusion criteria

Exclusion Criteria:

  • (1) Pregnant or lactating women; (2) Patients with intestinal dysfunction: including severe acute intestinal injury, intestinal obstruction or other diseases that affect the normal function of the intestine; (3) status: such as patients who use immunosuppressants, or patients with obvious immune dysfunction (such as infection, organ transplant patients, etc.); (4) Those who have recently undergone intestinal surgery or endoscopy; (5) The patient or his family failed to sign the or refused to participate in the study;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Intestinal flora structure

    Diversity of intestinal flora

    Time frame: one year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: starting 6 months after publication

Access criteria: The de-identified survey data will be made available for research purposes by contacting the corresponding authors

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jun 2027, 21 months later.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 21 months is below that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974682
Responsible party
Tang Ziren (professor, Capital Medical University) — Principal investigator
First posted
May 16, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Aug 27, 2025

Study contacts

Ziren Tang
Contact
tangziren1970@163.com
+86 010-85231530

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion